Transforming Neonatal Care Where Resources Are Limited
Neonatal Care
About Us
Founded in January 2026 by Dr. Vikram Sakaleshpur Kumar and Sakaleshpur Shiva Kumar, Sakaleshpur Shiva Shankara is a healthcare innovation startup developing practical, affordable medical solutions for newborn and pediatric care.
Our mission is to replace complex, infrastructure-heavy technologies with accessible interventions designed specifically for low-resource, rural, and point-of-care environments.
Lead Research (NeoLumo)
Point-of-Care Diagnostics & Tools
Evidence-Based Development
NEONATAL CARE
What We Do
Lead Research (NeoLumo)
An investigational topical zinc oxide nanogel designed as an alternative transdermal approach to manage newborn jaundice (neonatal hyperbilirubinemia). NeoLumo is being developed to complement standard care in peripheral clinics lacking reliable phototherapy units.
Point-of-Care Diagnostics & Tools
Low-cost accessories and simplified screening tools designed to help frontline health workers detect, monitor, and refer neonatal jaundice early.
Evidence-Based Development
We focus on practical, incremental advancements rooted in rigorous preclinical validation, patient safety, and regulatory compliance.
Current Status & Development Roadmap
Investigational Stage (TRL-4)
Our flagship innovation, NeoLumo, is currently at Technology Readiness Level 4 (TRL-4). As an investigational topical nanogel, it has demonstrated early proof-of-concept in lab settings and is not yet approved for clinical use or commercial distribution.
To advance NeoLumo systematically toward TRL-5, our ongoing research pipeline focuses on:
In-Vivo Animal Studies: Rigorous safety and efficacy evaluations in standardized Wistar rat models to determine systemic absorption, local tolerability, and bilirubin-lowering kinetics.
Formulation & Stability Refinement: Optimizing the zinc oxide nanogel matrix for extended shelf-life under diverse temperature conditions, ensuring stability in field and rural environments.
Dose Standardization: Defining precise dosing parameters, concentration safety margins, and transdermal permeation profiles.
We believe true healthcare impact requires patience, proof, and transparency:
Stepwise Validation: We adhere to strict preclinical progression benchmarks before initiating early-phase clinical evaluations.
Compliance & Safety: Development is aligned with national and international medical device and nanomedicine regulatory frameworks from day one.
Responsible Scale: Rather than rushing unverified claims to market, our priority remains the verifiable safety, reliability, and reproducible efficacy of our solutions.